BIOCORP Signs Distribution Agreement for Mallya Technology With Roche Diabetes Care France
30 Giugno 2020 - 7:30AM
Business Wire
The leader in self-monitoring of blood
glucose in France will distribute Mallya connected device to
pharmacists and will integrate it into its Roche Diabetes digital
ecosystem.
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME),
a French company specialized in the development and manufacturing
of medical devices and smart drug delivery systems, announces today
the signature of a distribution contract for its Mallya connected
device with Roche Diabetes Care France.
As part of the agreement, Roche Diabetes Care France will
distribute Mallya to pharmacies in France. This medical device is
an intelligent 2-year reusable injector pen sensor that is
compatible with the majority of insulin injection pens, both
disposable and reusable. It automatically collects the insulin dose
delivered with near 100% accuracy.
In the future, Mallya will also be
part of the RocheDiabetes ecosystem consisting of connected blood
glucose meters (Accu-Chek Mobile, Accu-Chek Guide) and digital
solutions for better patients care.
Gluci-Chek is a smartphone
application regularly used by nearly 60,000 diabetic patients in
France. It brings together three major functionalities for
personalized diabetes management: a carbohydrate calculation tool
with visualization of portions on the plate, a self-monitoring
glycemic logbook and a graphic visualization of glycemic
results.
Thanks to Mallya, the patient will no longer have to manually
report the insulin doses injected in the future since, once the
sensor is paired with the Gluci-Chek application, the data will be
automatically reported and displayed in the blood glucose
monitoring logbook, regardless of the insulin pen1.
Frédéric Jacquey, President of Roche Diabetes Care France: “The
signature of this agreement with Biocorp represents a fundamental
step in the development of our ecosystem to improve the care of
diabetic patients and their exchanges with healthcare
professionals. With innovative technology like Mallya, we will soon
be able to offer a unique offering for optimal patient care that
integrates blood glucose data from our meters via Gluci-Chek and
automatic insulin data via Mallya.”
Éric Dessertenne, CEO of BIOCORP: “Roche is the second
pharmaceutical giant to integrate our Mallya connected device for
optimal monitoring of diabetic patients into its commercial offer.
I would like to thank the teams at Roche Diabetes Care France for
their responsiveness over the last few weeks. This new structuring
agreement confirms the ambitions presented to all our shareholders
in early 2020 on the market of digitalization of diabetes and the
considerable commercial potential of Mallya. With a partner of the
calibre of Roche, we are confident that a large number of diabetics
will quickly be able to benefit from the real benefits offered by
Mallya on the secure monitoring of their daily insulin intake."
ABOUT DE ROCHE DIABETES CARE FRANCE Roche Diabetes Care is a
healthcare company specializing in diabetes. For more than 40
years, it has been designing solutions to meet the needs of both
patients and healthcare professionals: medical devices (blood
glucose meters, lancing devices, insulin pumps), services
(information and therapeutic education support) and digital
solutions (applications, platform for sharing blood glucose data
between patients and healthcare professionals). By creating an
ecosystem connecting medical devices and digital solutions, Roche
Diabetes Care is paving the way for personalized diabetes
management with the aim of facilitating and optimizing the
management and monitoring of this complex disease. Roche Diabetes
Care France is a subsidiary of the Roche Group in France, alongside
Roche SAS France and Roche Diagnostics France. For more
information, please visit www.roche.fr.
ABOUT BIOCORP Recognized for its expertise in the development
and manufacture of medical devices and delivery systems, BIOCORP
has today acquired a leading position in the connected medical
device market thanks to Mallya. This intelligent sensor for insulin
injection pens allows reliable monitoring of injected doses and
thus offers better compliance in the treatment of diabetics.
Available for sale from 2020, Mallya spearheads BIOCORP's product
portfolio of innovative connected solutions. The company has 54
employees. BIOCORP is listed on Euronext since July 2015
(FR0012788065 – ALCOR). For more information, please visit
www.biocorpsys.com. Follow us on Twitter @BIOCORPSystems
1 SoloStar de Sanofi – KwikPen de Eli Lilly – FlexPen de Novo
Nordisk
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200629005362/en/
BIOCORP CONTACTS Sylvaine Dessard rp@biocorp.fr + 33 (0)6 88 69
72 85
Bruno ARABIAN barabian@ulysse-communication.com +33 (0)6 87 88
46 26
ROCHE DIABETES CARE FRANCE CONTACTS Myriam Hamza rochediabpresse@havas.com +33 (0)6 45 87 46 51
Raphaële Badel Raphaele.badel@roche.com +33 (0)7 77 34 60 59
Grafico Azioni Biocorp (EU:ALCOR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Biocorp (EU:ALCOR)
Storico
Da Apr 2023 a Apr 2024